- FDA commercial approval. - The largest biotech deal done in this country. - Another US$87m in the bank (to go with the US$50m) - Royalties of 15%+ on global sales - up to US$195m in milestone payments - Eli Lilly to market and distribute - US market worth US$1b pa and growing at 20%pa (this is just US) - Conceivable they could get 35% market share. - will commence paying a dividend in 2011. - Potential to make a 50c per share special dividend.
And best of all, all dividends and capital gains are tax free due to pooled development fund status.
It will not be too long before the institutions line up to buy this. Expect strong media coverage to come.
$4-$5+ written all over it.
ACR Price at posting:
$3.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)